O ver 60 years have passed since the dramatic ad' vent of insulin to diabetes therapy. The indisputable improvement and survival of otherwise terminal insulin-dependent diabetic patients erased instantly any question of efficacy. However, multiple injections of rapid-acting insulin were needed to minimize the symptoms of hyperglycemia-the polydipsia and polyuria-until the longer-acting insulins with their greater convenience became available in the late 1930s. Even before the first use of insulin in 1922, and especially afterward, there were reports of both the macroangiopathic as well as the microangiopathic complications of the disease. Patients with these complications became more numerous in the late 1940s and the 1950s.
Much of the agendas of the American Diabetes Association meetings in the mid-1950s, which were then attended by 100 or 200 physicians and a scattering of Ph. D. 's, was devoted to often-heated discussions of whether the precise weighing of food, frequent urine testings, and accurate and rigid repetitive daily schedules for meals and exercise really did result in a major improvement in diabetes control and, if they all did, were there diminished complications?
In the 1960s and 1970s, an array of experimental diabetic animal data demonstrated that lesions similar to and in some cases indistinguishable from those seen in human diabetes were prevented and in some cases even reversed to a limited degree by appropriate restoration of insulin levels and diminution of hyperglycemia. These as well as some retrospective clinical data 1 prompted the American Diabetes Association to adopt the policy that attempts at better control of diabetes should be standard therapy, within the limits of life-style alteration tolerated by each individual. In the meantime, the striking improvement of the complications of diabetic pregnancy (except for the persistence of congenital anomalies, which are now being evaluated by studies in which better diabetic control is being achieved during prepregnancy and the first weeks of pregnancy) and the marked reduction of a number of other problems, particularly infections such as tuberculosis, also encouraged efforts to achieve better diabetes control in the hope that it would allay all of the complications of diabetes.
The final but yet indirect impetus toward improved diabetes control has been the demonstration that hyperglycemia can induce a large number of reversible physiologic functions, which include increases in vascular permeability, especially the renal vascular bed, altered erythrocyte, leukocyte, and platelet functions, delayed nerve conduction, axonal flow, etc. In addition the chemical characterization of a direct interaction between glucose and amino groups, be it the amino group at the N-terminus of a protein or a lysine molecule lying within the protein chain, has promulgated a more sophisticated and logical push toward euglycemia.
On the other hand there are the very rare reports of "classical" diabetic retinopathy or nephropathy in patients without prior hyperglycemia, or at least no prior demonstrable hyperglycemia. Conversely, there are the approximately one-in-four or one-in-five diabetic patients who have had moderate to even severe degrees of hyperglycemia over many decades and yet have only a few scattered microaneurysms and exudates in the optic fundus, perhaps minimal proteinuria, and thickened vascular basement membranes, but otherwise are doing well.
Obviously there is much more than a simple linear correlation between hyperglycemic-years and development of the "opathies"; this wide variability is what makes therapeutic correlations so difficult. It is not even known whether the glycosyl-amino bond is reversible, and if so, is the reaction enzymatic or nonenzymatic within living systems? If glucose is interacting with lysine groups or with N-terminal amino acids, why don't nondiabetic individuals develop the "opathies" in 2-3 times the duration they take to develop in the diabetic patient? Does the normal turnover of proteins continue to clean house or are the glycosylated proteins selectively removed, or worse and more likely, are they removed less well and therefore accumulate, as in the mesangium of the kidney? Is the removal process, if it does exist, under genetic control? If it is enzymatic, it certainly would be. Can patients eventually be divided into those who are more and those who are less at risk to develop the "opathies" and treatment graded accordingly? Possibly, and the questions could go on.
From a theoretical viewpoint as judged from the above, euglycemia appears most prudent, but the bottom line is whether it really does work and if so, is it clinically approachable. Is there a benefit in each little step-up of control in the attempt to bring glucose values closer toward normal, and is the benefit worth the effort? To answer this pragmatic and most important question, in fact, overwhelmingly the most important question facing anyone involved in diabetes management, the multicenter prospective randomized clinical trial [Protocol for Diabetes Control and Complications Trial (DCCT). Diabetes Care 1982; 5:XXIX.] is being initiated this year.
Setting aside all the experimental animal data, the theories surrounding protein-glucose interactions, the amazing success of the diabetes-pregnancy story, the multitude of retrospective studies, and the scattering of prospective reports both in America and abroad, the question is whether a further betterment of diabetes control in insulin-dependent diabetes does indeed significantly diminish the complications in a realistic cost-benefit ratio. One problem, of course, is that the "standard" therapy has already moved dramatically toward better control and so what will be studied is only any further incremental effect, thus making the differences in diabetes complications more difficult to detect, if indeed there are differences.
Nevertheless, the study must be done and one does not have to hark back to the bleeding of patients by physicians to remove poisons two centuries ago or the use of antihistamines for the common cold two decades ago for evidence of widely accepted wishful thinking by supposedly critical practitioners. The study cannot fail to provide very useful information. If a further significant improvement of glycemia is achieved and the parameters show a significant delaying of the complications, efforts will be made toward achieving this heightened degree of control more broadly, that is, as long as it is cost effective. If complications diminish without objective evidence of betterment of glucose levels or the other way around, our entire approach and its underlying hypotheses will need to be restructured. Meanwhile, the scientific community will not mark time but will continue efforts toward the prevention of new cases of insulin-dependent diabetes, which may diminish the need for the DCCT, but in the meantime it must be done.
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